In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regions.

Advanced prostate cancer Castration-naïve prostate cancer Castration-resistant prostate cancer Decision-making Genetics High-risk localized prostate cancer Hormone-sensitive prostate cancer Imaging Oligometastatic prostate cancer Overall survival Progression-free survival Prostate cancer treatment Tumour genomic profiling

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Apr 2021
Historique:
entrez: 26 7 2021
pubmed: 27 7 2021
medline: 27 7 2021
Statut: ppublish

Résumé

The rapid innovation of the treatment and diagnostic procedures in advanced prostate cancer has led to improved outcomes, though uncertainty remains regarding the best management approach in many clinical situations. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed these areas of uncertainty with a multidisciplinary, international expert panel. A total of 57 experts voted on 123 carefully prepared questions. The primary analysis of the APCCC 2019 showed consensus (≥ 75% agreement on one answer) for 33 questions. Here we investigate whether agreement with the consensus answers differed according to medical discipline and region of practice. Overall there was no compelling evidence for group differences of agreement with the consensus answers, i.e. expert sub-groups differed no more than could be expected by chance due to differences between individual experts. All questions that achieved consensus, had at least 50% agreement of each expert sub-group. Furthermore, the set of consensus questions changed only moderately if one of the sub-groups was excluded from the panel. The identification of consensus questions and answers at APCCC 2019 appeared to be robust to the composition of the panel and well supported.

Identifiants

pubmed: 34308382
doi: 10.1016/j.euros.2021.01.010
pmc: PMC8297969
mid: NIHMS1722061
doi:

Types de publication

Journal Article

Langues

eng

Pagination

14-17

Subventions

Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States

Références

JAMA. 2000 Jun 28;283(24):3217-22
pubmed: 10866869
Mayo Clin Proc. 2017 Jul;92(7):1164-1166
pubmed: 28688469
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Health Serv Res. 2006 Dec;41(6):2182-200
pubmed: 17116115
Eur Urol. 2020 Apr;77(4):508-547
pubmed: 32001144
BMJ. 2004 Dec 18;329(7480):1460-3
pubmed: 15604184
Cancer. 2006 May 1;106(9):1865-74
pubmed: 16568450
Ann Oncol. 2015 Aug;26(8):1589-604
pubmed: 26041764

Auteurs

Manolis Pratsinis (M)

Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Susan Halabi (S)

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.

Sabine Güsewell (S)

Biostatistics, Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Silke Gillessen (S)

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Università della Svizzera Italiana, Lugano, Switzerland.

Aurelius Omlin (A)

Medical Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Classifications MeSH